Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | AS3MT | Q9HBK9 | 2/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.43 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17187920 | 0.82 | ALOX5 (0.55) | ALOX5MAOBCYP3A4PLAUPLAT | |
| SCHEMBL17187860 | 0.80 | CYP1A2 (0.44) | — | |
| SCHEMBL275425 | 0.77 | IMPDH2 (0.66) | MAOBAS3MTNSD2IMPDH2MAOA | |
| SCHEMBL18428143 | 0.76 | ALOX5 (0.48) | ALOX5MAOBPLAUPLATEGLN2 | |
| SCHEMBL6036373 | 0.76 | MAOB (0.54) | ALOX5MAOBAS3MTNSD2SGMS2 | |
| SCHEMBL17188139 | 0.75 | ALOX5 (0.56) | ALOX5MAOBAS3MTNSD2IMPDH2 | |
| SCHEMBL20597194 | 0.75 | ALOX5 (0.46) | ALOX5MAOBCYP3A4PLAUPLAT | |
| SCHEMBL10606515 | 0.74 | ALOX5 (0.67) | ALOX5MAOBCYP3A4PLAUPLAT | |
| SCHEMBL3150218 | 0.74 | SGMS2 (0.66) | MAOBSGMS2CYP3A4MRGPRX4 | |
| SCHEMBL5326511 | 0.74 | MAOB (0.60) | MAOBNR4A2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134392-B1 | SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-01-02 | — | — | EP | disclosed |
| US-9840482-B2 | Sulfonamide derivatives and pharmaceutical applications thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-12-12 | — | — | US | disclosed |
| US-20170037017-A1 | Sulfonamide Derivatives And Pharmaceutical Applications Thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037017-A1 | Sulfonamide Derivatives And Pharmaceutical Applications Thereof | HTR6, SLC6A4, HTR2A | ALOX5 681/4885MAOB 250/4885AS3MT 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.